ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Phase 1

Terminated

Conditions: Breast Cancer
Cancer

Interventions: Drug: Venetoclax
Drug: Capecitabine

First Posted Date: 2020-02-18

Last Posted Date: 2020-10-29

Lead Sponsor: AbbVie

Target Recruit Count: 4

Registration Number: NCT04274933

Locations: 🇺🇸
Greenville Health System Cance /ID# 216059, Greenville, South Carolina, United States
🇩🇪
Universitaetsklinik Heidelberg /ID# 214679, Heidelberg, Baden-Wuerttemberg, Germany
🇵🇷
GCM Medical Group PSC - Hato Rey /ID# 216904, San Juan, Puerto Rico

and more 15 locations

A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Phase 1

Terminated

Conditions: Non Small Cell Lung Cancer
Cancer
Acute Myeloid Leukemia (AML)

Interventions: Drug: ABBV-184

First Posted Date: 2020-02-17

Last Posted Date: 2022-09-08

Lead Sponsor: AbbVie

Target Recruit Count: 14

Registration Number: NCT04272203

Locations: 🇯🇵
National Cancer Center Hospital East /ID# 216467, Kashiwa-shi, Chiba, Japan
🇮🇱
Tel Aviv Sourasky Medical Center /ID# 222749, Tel Aviv-Yafo, Tel-Aviv, Israel
🇫🇷
Hopital Saint-Andre /ID# 224218, Bordeaux, France

and more 14 locations

An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis (RA)

First Posted Date: 2020-02-13

Last Posted Date: 2023-01-26

Lead Sponsor: AbbVie

Target Recruit Count: 534

Registration Number: NCT04267536

Locations: 🇩🇪
Rheumahaus Studien GbR, Potsdam, DE /ID# 218430, Potsdam, Brandenburg, Germany
🇩🇪
Stille, Hanover, DE /ID# 218429, Hannover, Germany
🇩🇪
Praxis K. Pagel /ID# 218714, Hoppegarten, Germany

and more 49 locations

A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)

Phase 1

Terminated

Conditions: Atopic Dermatitis

Interventions: Device: Wrist Actigraphy Device
Device: Sleep Headband

First Posted Date: 2020-02-10

Last Posted Date: 2022-02-15

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT04262791

Locations: 🇺🇸
PPD Clinical Research Unit /ID# 217010, Orlando, Florida, United States
🇺🇸
Acpru /Id# 217345, Grayslake, Illinois, United States
🇺🇸
Univ Rochester Med Ctr /ID# 217490, Rochester, New York, United States

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Phase 1

Completed

Conditions: Ulcerative Colitis (UC)
Crohn's Disease

Interventions: Drug: Risankizumab
Drug: Cytochrome P450 (CYP) Substrates

First Posted Date: 2020-02-05

Last Posted Date: 2024-07-01

Lead Sponsor: AbbVie

Target Recruit Count: 20

Registration Number: NCT04254783

Locations: 🇺🇸
University Clinical Research /ID# 216823, DeLand, Florida, United States
🇺🇸
Southern California Res. Ctr. /ID# 216257, Coronado, California, United States
🇺🇸
Clinical Trials of Texas, Inc /ID# 216277, San Antonio, Texas, United States

and more 3 locations

A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

Completed

Conditions: Acute Myeloid Leukemia (AML)

First Posted Date: 2020-02-05

Last Posted Date: 2024-11-07

Lead Sponsor: AbbVie

Target Recruit Count: 51

Registration Number: NCT04253314

Locations: 🇷🇺
Hematology department State budgetary health care institution Volgograd region /ID# 229813, Volgograd, Volgogradskaya Oblast, Russian Federation
🇷🇺
Regional Clinical Hospital of Irkutsk /ID# 218570, Irkutsk, Russian Federation
🇷🇺
Clinical Medico-Sanitary Unit #1 /ID# 222502, Perm, Russian Federation

and more 7 locations

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)
HIV-1
HIV Infection

Interventions: Drug: Placebo
Drug: ABBV-181

First Posted Date: 2020-01-10

Last Posted Date: 2023-03-09

Lead Sponsor: AbbVie

Target Recruit Count: 41

Registration Number: NCT04223804

Locations: 🇺🇸
Franco Felizarta, Md /Id# 215721, Bakersfield, California, United States
🇺🇸
Ruane Clinical Research Group /ID# 224866, Los Angeles, California, United States
🇺🇸
Quest Clinical Research /ID# 215796, San Francisco, California, United States

and more 20 locations

A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2019-12-30

Last Posted Date: 2024-10-29

Lead Sponsor: AbbVie

Target Recruit Count: 50

Registration Number: NCT04214028

Locations: 🇯🇵
Kariya Toyota General Hospital /ID# 239046, Kariya-shi, Aichi, Japan
🇯🇵
Nagoya City University Hospital /ID# 238745, Nagoya shi, Aichi, Japan
🇯🇵
Meijo Hospital /ID# 250955, Nagoya-shi, Aichi, Japan

and more 51 locations

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Leukemia (SLL)
Cancer

First Posted Date: 2019-12-13

Last Posted Date: 2023-10-19

Lead Sponsor: AbbVie

Target Recruit Count: 4

Registration Number: NCT04198415

Locations: 🇯🇵
Nagoya City University Hospital /ID# 240820, Nagoya shi, Aichi, Japan
🇯🇵
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 239524, Nagoya-shi, Aichi, Japan
🇯🇵
Aso Iizuka Hospital /ID# 221140, Iizuka-shi, Fukuoka, Japan

and more 99 locations

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Completed

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-368
Drug: Tilsotolimod
Drug: Nab-paclitaxel
Drug: ABBV-181

First Posted Date: 2019-12-12

Last Posted Date: 2023-02-27

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT04196283

Locations: 🇺🇸
The University of Chicago Medical Center /ID# 217196, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center /ID# 214041, Houston, Texas, United States
🇺🇸
Norton Cancer Institute /ID# 216179, Louisville, Kentucky, United States

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy